Feature

Inventiva targeting MASH at its biological roots

By Melane Sampson Andrew Obenshain, CEO of Inventiva Inventiva (Euronext Paris and Nasdaq: IVA) is advancing development of an oral treatment for metabolic dysfunction-associated steatohepatitis (MASH) with its...

October 20, 2026

Feature

AIM advancing immunology solutions for globally important diseases

AIM ImmunoTech (NYSE American: AIM) is developing Ampligen, an immune modulator with potential applications across oncology, immune disorders, and viral diseases. The company is currently focused on developing Ampligen...

October 6, 2026

Feature

Akebia challenging the status quo in kidney disease

Akebia Therapeutics (NASDAQ: AKBA) is advancing the Nobel Prize-winning science behind hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) through its commercial product, Vafseo, an oral therapy designed...

September 29, 2026

Feature

Castle guiding patient management with gene expression profiling

Castle Biosciences (NASDAQ: CSTL) is helping clinicians move beyond traditional pathology using gene expression profiling to reveal the underlying biology of a patient’s tumor, enabling more personalized treatment and...

September 22, 2026

NEWS

PharmaJet highlights vaccine development opportunities and real-world impact with needle-free delivery at World Vaccine Congress Europe

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

Inventiva targeting MASH at its biological roots

AIM advancing immunology solutions for globally important diseases

Akebia challenging the status quo in kidney disease

Castle guiding patient management with gene expression profiling

NEWS

INmune submits pre-MAA to MHRA for Ebstrocel in RDEB

Valion’s interim CEO Dean Zikria unveils 30-day agenda to advance pipeline and maximize shareholder value

Findings identify Propanc’s PRP as potential strategy to reprogram chemo-resistant pancreatic cancer

Ironwood appoints Tammi Gaskins as CEO

PharmaJet highlights vaccine development opportunities and real-world impact with needle-free delivery at World Vaccine Congress Europe

TIME honors Perimeter’s Claire OCT with special mention on 2026 Best Innovations list

Valion’s next-gen NMR partnership with LarmorBio delivers initial feasibility milestone

FDA clears Edesa’s IND for Phase 2 vitiligo study

Jennifer Main joins Claritev’s board

Just a few of the companies we’ve highlighted along the way

Subscribe